Literature DB >> 14982741

CD8+ cell depletion amplifies the acute retroviral syndrome.

Lisa J Madden1, Michelle A Zandonatti, Claudia T Flynn, Mike A Taffe, M Cecilia G Marcondes, Jörn E Schmitz, Keith A Reimann, Steven J Henriksen, Howard S Fox.   

Abstract

The duration and severity of the symptomatology present during the early phase of human immunodeficiency virus (HIV) infection (known as the acute retroviral syndrome) is associated with alterations in the clinical profile of infection, such as a shortening of duration between infection with HIV and the onset of neurocognitive impairment and acquired immunodeficiency syndrome (AIDS). Viral-specific CD8+ cytotoxic T lymphocytes (CTLs) and CD8+ natural killer (NK) cells play a key role in antiviral immunity. Loss of CD8+ cells or their functional impairment during the early period of infection is associated with a rapid progression to AIDS in nonhuman primate studies. However, no studies have determined whether CD8+ cell loss or impairment is associated with symptoms of acute retroviral illness such as fever. In this study, the authors compared the early phase of simian immunodeficiency virus (SIV) infection in animals that were treated with the anti-CD8 monoclonal antibody cM-T807 to deplete CD8+ cells during the early period of infection (SIV+ CD8- group) to those with intact CD8+ cells (SIV+ CD8+ group). The SIV+ CD8- group had an enhanced acute retroviral syndrome when compared to the SIV+ CD8+ group. The SIV+ CD8- group also had prolonged high viral loads and distinct alterations in the proinflammatory cytokines interleukin (IL)-6 and interferon (IFN)-alpha, as well as in monocyte chemoattractant protein (MCP)-1. CD8+ cell depletion, therefore, appears to enhance symptoms of the acute retroviral syndrome and alters several of the immunological factors associated with the early phase of infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982741     DOI: 10.1080/753312754

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  40 in total

1.  Monokine products as predictors of AIDS dementia.

Authors:  L Pulliam; J A Clarke; M S McGrath; D Moore; D McGuire
Journal:  AIDS       Date:  1996-11       Impact factor: 4.177

Review 2.  The simian immunodeficiency viruses.

Authors:  R C Desrosiers
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

Review 3.  The acute retroviral syndrome and the pathogenesis of HIV-1 infection.

Authors:  S J Clark; G M Shaw
Journal:  Semin Immunol       Date:  1993-06       Impact factor: 11.130

4.  Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis.

Authors:  M C Zink; G D Coleman; J L Mankowski; R J Adams; P M Tarwater; K Fox; J E Clements
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

5.  Macaques with rapid disease progression and simian immunodeficiency virus encephalitis have a unique cytokine profile in peripheral lymphoid tissues.

Authors:  M S Orandle; K C Williams; A G MacLean; S V Westmoreland; A A Lackner
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication.

Authors:  P Cinque; L Vago; M Mengozzi; V Torri; D Ceresa; E Vicenzi; P Transidico; A Vagani; S Sozzani; A Mantovani; A Lazzarin; G Poli
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Longitudinal analysis of behavioral, neurophysiological, viral and immunological effects of SIV infection in rhesus monkeys.

Authors:  L H Gold; H S Fox; S J Henriksen; M J Buchmeier; M R Weed; M A Taffe; S Huitrón-Resendiz; T F Horn; F E Bloom
Journal:  J Med Primatol       Date:  1998 Apr-Jun       Impact factor: 0.667

10.  Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia.

Authors:  W Kelder; J C McArthur; T Nance-Sproson; D McClernon; D E Griffin
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  22 in total

Review 1.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

2.  Host response and dysfunction in the CNS during chronic simian immunodeficiency virus infection.

Authors:  Eleanor S Roberts; Salvador Huitron-Resendiz; Michael A Taffe; Maria Cecilia G Marcondes; Claudia T Flynn; Caroline M Lanigan; Jennifer A Hammond; Steven R Head; Steven J Henriksen; Howard S Fox
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

3.  Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

Authors:  P Vivithanaporn; G Heo; J Gamble; H B Krentz; A Hoke; M J Gill; C Power
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

4.  Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Authors:  Agneta von Gegerfelt; Antonio Valentin; Candido Alicea; Koen K A Van Rompay; Marta L Marthas; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2010-08-11       Impact factor: 5.422

Review 5.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

6.  CD8+ cell depletion of SHIV89.6P-infected macaques induces CD4+ T cell proliferation that contributes to increased viral loads.

Authors:  Yvonne M Mueller; Duc H Do; Jean D Boyer; Muhamuda Kader; Joseph J Mattapallil; Mark G Lewis; David B Weiner; Peter D Katsikis
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

Review 7.  Virus-host interaction in the simian immunodeficiency virus-infected brain.

Authors:  Howard S Fox
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

8.  A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses.

Authors:  Takeo Kuwata; Russell Byrum; Sonya Whitted; Robert Goeken; Alicia Buckler-White; Ronald Plishka; Ranjini Iyengar; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

9.  Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Ronald S Veazey; Paula M Acierno; Kimberly J McEvers; Susanne H C Baumeister; Gabriel J Foster; Melisa D Rett; Michael H Newberg; Marcelo J Kuroda; Kenneth Williams; Eun-Young Kim; Steven M Wolinsky; E Peter Rieber; Michael Piatak; Jeffrey D Lifson; David C Montefiori; Charles R Brown; Vanessa M Hirsch; Jörn E Schmitz
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

10.  CD4 deficits and disease course acceleration can be driven by a collapse of the CD8 response in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Maria Cecilia G Marcondes; Sieghart Sopper; Ulrike Sauermann; Tricia H Burdo; Debbie Watry; Michelle Zandonatti; Howard S Fox
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.